MXPA04002449A - Cristales de derivado de hidroxinorefedrina. - Google Patents

Cristales de derivado de hidroxinorefedrina.

Info

Publication number
MXPA04002449A
MXPA04002449A MXPA04002449A MXPA04002449A MXPA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A MX PA04002449 A MXPA04002449 A MX PA04002449A
Authority
MX
Mexico
Prior art keywords
crystals
ethyl
hydroxynorephedrine
derivative
hydroxynorephedrine derivative
Prior art date
Application number
MXPA04002449A
Other languages
English (en)
Inventor
Harada Hiromu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MXPA04002449A publication Critical patent/MXPA04002449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invencion proporciona un clorhidrato de etil (-)-2- [4-[2- [[(1S,2R) -2-hidroxi-2- (4-hidroxifenil)-1 -metiletil] amino]etil]-2, 5- dimetilfenoxi] acetato, formas cristalinas del mismo y composiciones farmaceuticas que los contienen, que tienen excelentes efectos estimulantes de ??3-adrenoceptor, efectos terapeuticos en polakiuria o incontinencia urinaria y estabilidades de almacenamiento y son utiles como un medicamento.
MXPA04002449A 2001-09-13 2002-08-27 Cristales de derivado de hidroxinorefedrina. MXPA04002449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001277345 2001-09-13
PCT/JP2002/008596 WO2003024916A1 (fr) 2001-09-13 2002-08-27 Cristaux d'un derive d'hydroxynorephedrine

Publications (1)

Publication Number Publication Date
MXPA04002449A true MXPA04002449A (es) 2004-07-23

Family

ID=19101883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002449A MXPA04002449A (es) 2001-09-13 2002-08-27 Cristales de derivado de hidroxinorefedrina.

Country Status (29)

Country Link
US (1) US7208520B2 (es)
EP (1) EP1426355B1 (es)
JP (1) JP4157036B2 (es)
KR (2) KR20080098691A (es)
CN (1) CN1275936C (es)
AT (1) ATE411276T1 (es)
AU (1) AU2002330453B2 (es)
BR (1) BR0212494A (es)
CA (1) CA2458544C (es)
CO (1) CO5560555A2 (es)
CY (1) CY1109409T1 (es)
DE (1) DE60229404D1 (es)
DK (1) DK1426355T3 (es)
EA (1) EA006022B1 (es)
EC (1) ECSP045017A (es)
ES (1) ES2314092T3 (es)
HK (1) HK1070051A1 (es)
HR (1) HRP20040250A2 (es)
HU (1) HUP0401694A3 (es)
IL (2) IL160681A0 (es)
MX (1) MXPA04002449A (es)
NO (1) NO328252B1 (es)
NZ (1) NZ531602A (es)
PL (1) PL206246B1 (es)
PT (1) PT1426355E (es)
SI (1) SI1426355T1 (es)
UA (1) UA77000C2 (es)
WO (1) WO2003024916A1 (es)
ZA (1) ZA200401757B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
CA2524023C (en) * 2003-05-05 2011-11-22 Kissei Pharmaceutical Co., Ltd. Use of phenoxyacetic acid derivatives for treating hyperactive bladder
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
MXPA06004625A (es) * 2003-11-03 2006-06-27 Boehringer Ingelheim Int Composicion famaceutica que contiene un agonista de un adrenoceptor beta-3 y un antagonista alfa y/o un inhibidor de la 5-alfa-reductasa.
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
ATE368639T1 (de) * 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
US20090247781A1 (en) 2004-10-26 2009-10-01 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
JPWO2006118087A1 (ja) * 2005-04-26 2008-12-18 キッセイ薬品工業株式会社 ヒドロキシノルエフェドリン誘導体塩酸塩・１／４水和物の結晶
US7763654B2 (en) 2005-04-26 2010-07-27 Kissei Pharmaceutical Co., Ltd. Crystal polymorph of hydroxynorephedrin derivative hydrochloride
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
KR20140143461A (ko) 2007-08-06 2014-12-16 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TR201819189T4 (tr) 2008-05-21 2019-01-21 Ferring Bv Noktüri İle Bozulmayan İlk Uyku Periyodunun Arttırılması İçin Ağızda Dağılan Desmopressin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
JP4005731B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体の結晶多形
JP4005730B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形
JP4005729B2 (ja) * 1999-01-21 2007-11-14 キッセイ薬品工業株式会社 アミノエチルフェノキシ酢酸誘導体二水和物の結晶多形

Also Published As

Publication number Publication date
EA006022B1 (ru) 2005-08-25
PL206246B1 (pl) 2010-07-30
ECSP045017A (es) 2004-09-27
CY1109409T1 (el) 2014-07-02
IL160681A0 (en) 2004-08-31
BR0212494A (pt) 2004-08-24
SI1426355T1 (sl) 2009-02-28
EP1426355A4 (en) 2006-03-29
WO2003024916A1 (fr) 2003-03-27
HUP0401694A2 (hu) 2004-11-29
CN1553890A (zh) 2004-12-08
ZA200401757B (en) 2005-03-03
CO5560555A2 (es) 2005-09-30
NZ531602A (en) 2006-01-27
ES2314092T3 (es) 2009-03-16
HRP20040250A2 (en) 2005-02-28
JPWO2003024916A1 (ja) 2004-12-24
UA77000C2 (en) 2006-10-16
EA200400311A1 (ru) 2004-08-26
DK1426355T3 (da) 2009-02-23
ATE411276T1 (de) 2008-10-15
US20040242686A1 (en) 2004-12-02
KR20040044881A (ko) 2004-05-31
EP1426355B1 (en) 2008-10-15
KR20080098691A (ko) 2008-11-11
US7208520B2 (en) 2007-04-24
NO328252B1 (no) 2010-01-18
NO20041060L (no) 2004-06-11
HUP0401694A3 (en) 2008-03-28
CA2458544A1 (en) 2003-03-27
JP4157036B2 (ja) 2008-09-24
CN1275936C (zh) 2006-09-20
PL367874A1 (en) 2005-03-07
IL160681A (en) 2010-06-16
AU2002330453B2 (en) 2008-04-17
EP1426355A1 (en) 2004-06-09
CA2458544C (en) 2010-08-17
KR100874952B1 (ko) 2008-12-19
DE60229404D1 (de) 2008-11-27
PT1426355E (pt) 2008-11-03
HK1070051A1 (en) 2005-06-10

Similar Documents

Publication Publication Date Title
MXPA04002449A (es) Cristales de derivado de hidroxinorefedrina.
GEP20043238B (en) Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EP2161265A3 (en) Compounds having selective inhibiting effect at GSK3
AU7071096A (en) Peripherally active anti-hyperalgesic opiates
AR033542A1 (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamicos
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
MY126489A (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
WO2002089782A3 (en) Dioxanes and uses thereof
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
RU2004116347A (ru) Соединения кремния
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
SE9900190D0 (sv) New compounds
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
EP0372941A3 (en) Anti-inflammatory 5-hydroxy-2-furanones
WO2003018564A1 (fr) Inhibiteur d'acat selectif de la paroi vasculaire
DE60300683D1 (de) Prucaloprid-n-oxid
AR044169A1 (es) Uso de derivados del acido fenoxiacetico para el tratamiento de la vejiga hiperactiva
WO2023235837A3 (en) 4-(3h-pyrazolo[4,3-f]quinolin-7-yl)-n-(2-(dimethylamino)ethyl)benzamide- or hydroxamic acid compounds, compositions, and methods of use
RU2001104896A (ru) Производные фенилового эфира альфа-аминокислоты
US20080140450A1 (en) Treatment of metabolic syndrome with norfluoxetine

Legal Events

Date Code Title Description
FG Grant or registration